Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 4,025,930 shares, a decrease of 16.7% from the January 15th total of 4,830,166 shares. Currently, 5.7% of the company’s stock are short sold. Based on an average daily volume of 751,145 shares, the days-to-cover ratio is presently 5.4 days. Based on an average daily volume of 751,145 shares, the days-to-cover ratio is presently 5.4 days. Currently, 5.7% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Morgan Stanley decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the sale, the insider directly owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. The trade was a 53.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares in the company, valued at $380,972.97. The trade was a 16.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 7,546,617 shares of company stock valued at $10,088,417. Corporate insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in Zentalis Pharmaceuticals by 177.6% in the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the period. Tybourne Capital Management HK Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after buying an additional 516,666 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Zentalis Pharmaceuticals during the second quarter valued at approximately $38,000. Finally, Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at approximately $59,000.

Zentalis Pharmaceuticals Trading Down 1.3%

Shares of ZNTL stock opened at $2.36 on Wednesday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.95. The stock has a market capitalization of $170.51 million, a P/E ratio of -1.14 and a beta of 1.73. The firm’s 50 day moving average is $2.22 and its 200 day moving average is $1.77.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.